Company intelligence / Profile preview

Axial

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

Axial Biotech developed and commercialized ScoliScore AIS Prognostic Test, a DNA-based diagnostic that predicts risk of curve progression in adolescent idiopathic scoliosis; rights to the test were acquired by Transgenomic in 2012, and Axial Biotech ceased operations around 2013.[1]

Therapeutic areas: NeurologyRheumatology
Modalities: Non-pharmacological therapyDevice
Industry: Molecular Diagnostics

Partnerships

DePuy Spine (distribution partner for ScoliScore AIS Prognostic Test)Transgenomic (acquired rights to ScoliScore test)

Beyond the preview

Go deeper on Axial.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axial.

Explore the full profile